1. Interferon γ release assay (IGRA) testing in mycobacterium tuberculosis screening prior to anti-tnf treatment: experience across 3 medical specialities. (13th March 2011) Authors: Foster, R A; Shah, M; Hale, M; Grant, W; Abdulrehman, A; Kuet, K P; Wright, A; Robinson, K; Mark, P; Butler, L; Gawkrodger, D; McAlindon, M; Ridgeway, E; Tattersall, R; Chapman, A; Lobo, A Journal: Gut Issue: Volume 60:(2011)Supplement 1 Page Start: A144 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction and estimating benefits from novel interventions. (25th November 2020) Authors: Welsh, P; Welsh, C; Celis-Morales, C.A.C; Brown, R; Ferguson, L.D; Gray, S; Mark, P; Lewsey, J; Lyall, D.M; Gill, J.M.R; Pell, J; Jhund, P.S; De Lemos, J.A; Willeit, P; Sattar, N Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SAT0198 Tocilizumab for the management of rheumatoid arthritis: discontinuation due to inefficacy and toxicity – experience from a large teaching hospital. (15th June 2017) Authors: Byrne, E; Mark, P; Khalid, S; Kuet, K-P; Kilding, R; Graves, K; Maxwell, J; Akil, M Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 847 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗